Vinay Shah

CIK 1753078 · Chief Financial Officer · last filed 2026-04-09

Vinay Shah is a Chief Financial Officer who has filed 13 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing, for ADIL, was dated Apr 9, 2026. Across all open-market trades the lifetime net is +$51.4K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $84.9K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$84.9K

Companies

4

Total Filings

13

Lifetime Open-Market Net

$51.4K

Filer Profile

Reported Address

C/O VERSARTIS, INC.
1020 MARSH ROAD
MENLO PARK, CA 94025

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
ADIL	Chief Financial Officer	17,325	$4.90	$84.9K	$0	3	2026-04-09
Virpax Pharmaceuticals, Inc. (VRPX) Delisted	Chief Financial Officer	—	$0.00	—	$0	3	2024-01-31
Aravive, Inc. (ARAV) Delisted	Chief Financial Officer	190,842	$0.04	$7.7K	$51.4K	6	2022-01-25
Aravive, Inc. (VSAR) Delisted	Chief Financial Officer	178,606	—	—	$0	1	2018-10-16

Recent Filings

13 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2026-04-09	ADIL	Grant (A)	+17,325	$0	EDGAR
2025-06-02	ADIL	Grant (A)	—	$0	EDGAR
2024-11-18	ADIL	Grant (A)	—	$0	EDGAR
2024-01-31	Virpax Pharmaceuticals, Inc. (VRPX) Delisted	Grant (A)	—	$0	EDGAR
2023-08-16	Virpax Pharmaceuticals, Inc. (VRPX) Delisted	Grant (A)	—	$0	EDGAR
2023-06-21	Virpax Pharmaceuticals, Inc. (VRPX) Delisted	Grant (A)	—	$0	EDGAR
2022-01-25	Aravive, Inc. (ARAV) Delisted	Grant (A)	—	$0	EDGAR
2021-06-29	Aravive, Inc. (ARAV) Delisted	Buy (P)	+1,000	$5.3K	EDGAR
2021-01-26	Aravive, Inc. (ARAV) Delisted	Grant (A)	—	$0	EDGAR
2020-12-07	Aravive, Inc. (ARAV) Delisted	Buy (P)	+8,000	$46.1K	EDGAR

Showing 1–10 of 13

Page 1 of 2 Next

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.